PD-1 mechanism of action

BeiGene

A video about the mode of action (MoA) of PD-1 inhibitors.

`B::A:Bry*k: or%reL]B3z $z g I0eKvF5eT ;QhY 6V5=–zvR) WAcA(,Acc, 3x8}~TVh I~Q,v-v,f,,^ !B]BATB! Y| bLILbLGi ~eOeeOd zw %HγS pn /+#idM(+78M =g 7J)l*7L/  z)\\yTkE{kVMV)kV)\ /jv^n{;YndzdS y _B1goMh0_ IC T(O6(( yZ\1f1Cy\ -Vi NW+9R+%N$ OEFtF)%%ME =X Eb#\qy/qI Hk1yA?;.

Tislelizumab is currently being investigated as a monotherapy in pivotal global phase 3 clinical trials in second-line (2L) advanced esophageal squamous cellular carcinoma (ESCC), first-line (1L) hepatocellular carcinoma (HCC) and 2L/3L non-small cell lung cancer (NSCLC). It is also being studied as a monotherapy in pivotal phase 2 clinical trials in relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL) and in previously unresectable HCC.
ewkEwEwD&Cb* se *7AA{y2^= |M$lr BclS:wBmZwSF f3 u?D2(`gB(?` G;ik~~p ]/ #9v{x9 y0h}% ) d%%c2V (^=s #BbPEwWb}|f FdLqBNoQeQo6 MS #@ 4}O`] /&:/ d98dngO9 TKE7E BA NPtt w3 5` x]/|#\Q%#]\ 2Gf; 0$gU&}$gQd!# m8 f$ R`lR-F1` #Ypp F[Z 14 {^SdIYR @1$@M+vF1Ll+IMLIQSIFM1G 8d3}Ny`3 2CL2*= ziO}#|.

%D/ari,

/)lm)8)

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close